Best available treatment

DRUG5 trials

Conditions

Acute PyelonephritisBacteremiaCovid19Distress Respiratory SyndromeEssential ThrombocythemiaHospital Acquired PneumoniaIntra-abdominal InfectionLeukemia, Chronic Myelogenous

Phase 2

Clinical Trial of Sarilumab in Adults With COVID-19

CompletedNCT04357860

Maimónides Biomedical Research Institute of CórdobaSARS, SARS-CoV 2

Start: 2020-04-28End: 2021-04-06Updated: 2021-07-07

Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19

CompletedNCT04745442

Maimónides Biomedical Research Institute of CórdobaCovid19, Distress Respiratory Syndrome, Severe Acute Respiratory Syndrome

Start: 2020-04-27End: 2021-01-15Updated: 2021-02-09

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

CompletedNCT04795427

Novartis PharmaceuticalsLeukemia, Chronic Myelogenous

Start: 2021-12-06End: 2024-11-18Updated: 2025-04-18

Phase 3

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

RecruitingNCT07623200

Incyte CorporationEssential Thrombocythemia

Start: 2026-09-08End: 2030-11-01Target: 426Updated: 2026-09-14

Phase 4

Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

CompletedNCT04882085

PfizerAcute Pyelonephritis, Bacteremia, Hospital Acquired Pneumonia +3

Start: 2021-08-26End: 2023-08-31Updated: 2024-10-21

Related Papers

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.

2022-12-0128 citations

Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.

2021-12-1327 citations

Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

BMJ Open2020-11-0116 citations